Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
119.86
-0.29 (-0.24%)
Apr 14, 2026, 10:54 AM EDT - Market open
Merck & Co. Market Cap
Merck & Co. has a market cap or net worth of $296.04 billion as of April 14, 2026. Its market cap has increased by 33.01% in one year.
Market Cap
296.04B
Enterprise Value
331.27B
1-Year Change
33.01%
Ranking
Category
Stock Price
$119.86
Market Cap Chart
Since December 1, 1998, Merck & Co.'s market cap has increased from $187.00B to $296.04B, an increase of 58.31%. That is a compound annual growth rate of 1.69%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 10, 2026 | 300.20B | 14.90% |
| Dec 31, 2025 | 261.26B | 3.82% |
| Dec 31, 2024 | 251.65B | -8.91% |
| Dec 29, 2023 | 276.26B | -1.79% |
| Dec 30, 2022 | 281.30B | 45.31% |
| Dec 31, 2021 | 193.59B | -6.46% |
| Dec 31, 2020 | 206.96B | -10.62% |
| Dec 31, 2019 | 231.56B | 16.54% |
| Dec 31, 2018 | 198.69B | 29.61% |
| Dec 29, 2017 | 153.30B | -5.55% |
| Dec 30, 2016 | 162.31B | 10.00% |
| Dec 31, 2015 | 147.55B | -8.86% |
| Dec 31, 2014 | 161.90B | 10.71% |
| Dec 31, 2013 | 146.24B | 17.50% |
| Dec 31, 2012 | 124.46B | 8.31% |
| Dec 30, 2011 | 114.91B | 3.49% |
| Dec 31, 2010 | 111.03B | 44.07% |
| Dec 31, 2009 | 77.07B | 19.91% |
| Dec 31, 2008 | 64.27B | -49.18% |
| Dec 31, 2007 | 126.48B | 33.62% |
| Dec 29, 2006 | 94.66B | 36.08% |
| Dec 30, 2005 | 69.56B | -2.41% |
| Dec 31, 2004 | 71.27B | -30.66% |
| Dec 31, 2003 | 102.79B | -19.14% |
| Dec 31, 2002 | 127.12B | -4.96% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 573.15B |
| AbbVie | 365.20B |
| AstraZeneca | 312.72B |
| Novartis AG | 294.69B |
| Amgen | 188.79B |
| Gilead Sciences | 172.57B |
| Novo Nordisk | 165.61B |
| Pfizer | 153.13B |